2. Academic Validation
  3. Indoleamine 2,3-dioxygenase 1 inhibition reverses cancer-associated fibroblast-mediated immunosuppression in high-grade serous ovarian cancer

Indoleamine 2,3-dioxygenase 1 inhibition reverses cancer-associated fibroblast-mediated immunosuppression in high-grade serous ovarian cancer

  • FEBS Open Bio. 2025 Oct 13. doi: 10.1002/2211-5463.70126.
Hyewon Lee 1 2,  Jung Yoon Ho 1 2,  In Sun Hwang 1,  Youn Jin Choi 1 2
Affiliations

Affiliations

  • 1 Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • 2 Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.
PMID: 41078340 DOI: 10.1002/2211-5463.70126
Abstract

Cancer-associated fibroblasts (CAFs) contribute to immunosuppression in the ovarian Cancer microenvironment, partly through upregulation of indoleamine 2,3-dioxygenase 1 (IDO1). This study examined CAF-mediated suppression of T-cell function and the potential of IDO1 inhibition to reverse these effects. CAFs from high-grade serous ovarian Cancer (HGSOC) patients exhibited increased IDO1, COX2, and PD-L1 expression upon interaction with activated T cells, along with elevated immunosuppressive cytokines. CAFs suppressed T-cell proliferation and induced PD-1 expression in CD4+ and CD8+ T cells, effects reversed by epacadostat. IDO1 inhibition enhanced T-cell proliferation via Akt signaling, restored T-cell cytotoxicity, and increased ovarian Cancer cell Apoptosis. These findings suggest that targeting IDO1 may help counteract CAF-mediated immunosuppression and enhance antitumor immunity in HGSOC.

Keywords

IDO1; cancer‐associated fibroblasts; immunosuppression; ovarian cancer; tumor microenvironment.

Figures
Products